The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

It included 432 individuals over 12 years of age who had plaque psoriasis affecting up to 25% of the scalp and body, with a minimum scalp IGA score of 3 and body IGA score of 2. Average age was 47.3 ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Moderate to severe scalp psoriasis severely affects quality of ... subgroup analyses assessed the proportion of patients achieving the minimum clinically important difference (MCID), defined ...

It included 432 individuals over 12 years of age who had plaque psoriasis affecting up to 25% of the scalp and body, with a minimum scalp IGA score of 3 and body IGA score of 2. Average age was 47 ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...